QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • CytRx (CYTR) To Present Global Phase 2b Clinical Data For Aldoxorubicin At Annual Connective Tissue Oncology Society Meeting 0 comments
    Oct 25, 2013 11:11 AM | about stocks: CYTR

    Oncology-focused biopharmaceutical research and development company CytRx Corporation announced it will present additional preliminary data from its Phase 2b clinical trial - demonstrating aldoxorubicin's potential advantage over doxorubicin in treating soft tissue sarcoma (NYSEMKT:STS) - at the 18th Annual Connective Tissue Oncology Society (CTOS) Meeting, taking place Thursday, Oct. 31 in the Sheraton New York Times Square Hotel.

    CytRx previously reported that patients in the trial who were treated with aldoxorubicin had an overall response rate (ORR) of 22 percent, as opposed to those administered the widely used chemotherapeutic agent doxorubicin, who had an ORR of 0 percent. CytRx plans to report topline data for the global Phase 2 clinical trial in December of this year.

    CTOS attracts sarcoma treatment leaders from around the world, making it an ideal forum for CytRx to spread awareness of this data and to also acquaint oncologists with its Phase 3 study in patients with relapsed or refractory soft tissue sarcomas. There have been relatively few discoveries of new sarcoma treatments, particularly when compared with treatments for breast or prostate cancer, but these preliminary clinical results have fueled CytRx's optimism that aldoxorubicin can fill an important medical need in patients with advanced soft tissue sarcoma.

    Soft tissue sarcoma is a cancer that occurs in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. There are more than 30 types of STS, and it can arise anywhere in the body at any age. According to the American Cancer Society, more than 10,500 new cases are diagnosed in the U.S. each year.

    In addition to its Phase 2b trial for STS, CytRx has received acceptance from the FDA for a protocol to conduct a Phase 2 clinical trial with aldoxorubicin in glioblastoma, a deadly brain cancer that is difficult to treat. The company also plans to conduct a Phase 2 clinical trial in HIV-related Kaposi's sarcoma.

    For more information, visit cytrx.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: CYTR
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.